Cargando…
Liver Effects of Clinical Drugs Differentiated in Human Liver Slices
Drugs with clinical adverse effects are compared in an ex vivo 3-dimensional multi-cellular human liver slice model. Functional markers of oxidative stress and mitochondrial function, glutathione GSH and ATP levels, were affected by acetaminophen (APAP, 1 mM), diclofenac (DCF, 1 mM) and etomoxir (ET...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372590/ https://www.ncbi.nlm.nih.gov/pubmed/28272341 http://dx.doi.org/10.3390/ijms18030574 |
_version_ | 1782518650377338880 |
---|---|
author | Vickers, Alison E. M. Ulyanov, Anatoly V. Fisher, Robyn L. |
author_facet | Vickers, Alison E. M. Ulyanov, Anatoly V. Fisher, Robyn L. |
author_sort | Vickers, Alison E. M. |
collection | PubMed |
description | Drugs with clinical adverse effects are compared in an ex vivo 3-dimensional multi-cellular human liver slice model. Functional markers of oxidative stress and mitochondrial function, glutathione GSH and ATP levels, were affected by acetaminophen (APAP, 1 mM), diclofenac (DCF, 1 mM) and etomoxir (ETM, 100 μM). Drugs targeting mitochondria more than GSH were dantrolene (DTL, 10 μM) and cyclosporin A (CSA, 10 μM), while GSH was affected more than ATP by methimazole (MMI, 500 μM), terbinafine (TBF, 100 μM), and carbamazepine (CBZ 100 μM). Oxidative stress genes were affected by TBF (18%), CBZ, APAP, and ETM (12%–11%), and mitochondrial genes were altered by CBZ, APAP, MMI, and ETM (8%–6%). Apoptosis genes were affected by DCF (14%), while apoptosis plus necrosis were altered by APAP and ETM (15%). Activation of oxidative stress, mitochondrial energy, heat shock, ER stress, apoptosis, necrosis, DNA damage, immune and inflammation genes ranked CSA (75%), ETM (66%), DCF, TBF, MMI (61%–60%), APAP, CBZ (57%–56%), and DTL (48%). Gene changes in fatty acid metabolism, cholestasis, immune and inflammation were affected by DTL (51%), CBZ and ETM (44%–43%), APAP and DCF (40%–38%), MMI, TBF and CSA (37%–35%). This model advances multiple dosing in a human ex vivo model, plus functional markers and gene profile markers of drug induced human liver side-effects. |
format | Online Article Text |
id | pubmed-5372590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53725902017-04-10 Liver Effects of Clinical Drugs Differentiated in Human Liver Slices Vickers, Alison E. M. Ulyanov, Anatoly V. Fisher, Robyn L. Int J Mol Sci Article Drugs with clinical adverse effects are compared in an ex vivo 3-dimensional multi-cellular human liver slice model. Functional markers of oxidative stress and mitochondrial function, glutathione GSH and ATP levels, were affected by acetaminophen (APAP, 1 mM), diclofenac (DCF, 1 mM) and etomoxir (ETM, 100 μM). Drugs targeting mitochondria more than GSH were dantrolene (DTL, 10 μM) and cyclosporin A (CSA, 10 μM), while GSH was affected more than ATP by methimazole (MMI, 500 μM), terbinafine (TBF, 100 μM), and carbamazepine (CBZ 100 μM). Oxidative stress genes were affected by TBF (18%), CBZ, APAP, and ETM (12%–11%), and mitochondrial genes were altered by CBZ, APAP, MMI, and ETM (8%–6%). Apoptosis genes were affected by DCF (14%), while apoptosis plus necrosis were altered by APAP and ETM (15%). Activation of oxidative stress, mitochondrial energy, heat shock, ER stress, apoptosis, necrosis, DNA damage, immune and inflammation genes ranked CSA (75%), ETM (66%), DCF, TBF, MMI (61%–60%), APAP, CBZ (57%–56%), and DTL (48%). Gene changes in fatty acid metabolism, cholestasis, immune and inflammation were affected by DTL (51%), CBZ and ETM (44%–43%), APAP and DCF (40%–38%), MMI, TBF and CSA (37%–35%). This model advances multiple dosing in a human ex vivo model, plus functional markers and gene profile markers of drug induced human liver side-effects. MDPI 2017-03-07 /pmc/articles/PMC5372590/ /pubmed/28272341 http://dx.doi.org/10.3390/ijms18030574 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vickers, Alison E. M. Ulyanov, Anatoly V. Fisher, Robyn L. Liver Effects of Clinical Drugs Differentiated in Human Liver Slices |
title | Liver Effects of Clinical Drugs Differentiated in Human Liver Slices |
title_full | Liver Effects of Clinical Drugs Differentiated in Human Liver Slices |
title_fullStr | Liver Effects of Clinical Drugs Differentiated in Human Liver Slices |
title_full_unstemmed | Liver Effects of Clinical Drugs Differentiated in Human Liver Slices |
title_short | Liver Effects of Clinical Drugs Differentiated in Human Liver Slices |
title_sort | liver effects of clinical drugs differentiated in human liver slices |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372590/ https://www.ncbi.nlm.nih.gov/pubmed/28272341 http://dx.doi.org/10.3390/ijms18030574 |
work_keys_str_mv | AT vickersalisonem livereffectsofclinicaldrugsdifferentiatedinhumanliverslices AT ulyanovanatolyv livereffectsofclinicaldrugsdifferentiatedinhumanliverslices AT fisherrobynl livereffectsofclinicaldrugsdifferentiatedinhumanliverslices |